

Index

Note: Page numbers set **bold** or *italic* indicate headings or figures, respectively.

A

- Ablative lasers 272
Ablative resurfacing lasers 336
Absorbable sutures 254, 255
Academic medicine 421
Acanthosis nigricans. 120
Accreditation Council for
Graduate Medical Education
(ACGME)-approved
fellowships 411
– dermatopathology 411
– training and scope of
practice for 411
– dermatopathology
fellowships, application
process for 412
– micrographic surgery and
dermatologic oncology
(MSDO) fellowship 411
– application process for 411
– training and scope of
practice for 411
– micrographic surgery and
dermatologic oncology
fellowship 411
– pediatric dermatology 412
– training and scope of
practice for 412
– pediatric dermatology
fellowships, application
process for 412
ACE inhibitor, *see* Angiotensin-
converting enzyme (ACE)
inhibitor
ACGME-approved fellowships,
see Accreditation Council for
Graduate Medical Education
(ACGME)-approved
fellowships
Acne keloidalis nuchae 167
Acne vulgaris 28
– inflammatory link in 119
Acquired dermal macular
hyperpigmentation
(ADMH) 91
Acquired disorders of the
connective tissues 131
Acrodermatitis
enteropathica 373
Acropustulosis of infancy 405
Actinic cheilitis 174
Actinic keratoses (AKs) 191,
191
Actinic prurigo 404
Acute cutaneous lupus
erythematosus 105
Acute generalized
exanthematous pustulosis
(AGEP) 70
AD, *see* Atopic dermatitis (AD)
ADM, *see* Amyopathic DM
(ADM)
ADMH, *see* Acquired dermal
macular hyperpigmentation
(ADMH)
Adnexal and pigmentary
disorders of skin 86
– hair follicle tumors,
examples of 86
– pigmentary disorder 88
– hyperpigmentation
disorders 90, 90
– hypopigmentation
disorders 88, 89
– sweat gland tumors 87, 87
Adson-Brown forceps 261
Adult idiopathic DM 108
AGEP, *see* Acute generalized
exanthematous pustulosis
(AGEP)
Aging and photoaging 317
– aging process 317
– intrinsic aging and extrinsic
aging 317
– treatment options 317
Aicardia-Goutieres
syndrome 372
AKs, *see* Actinic keratoses
(AKs)
Allergic disorders of oral
mucosa 173
Allylamines 138
Alopecia areata 164
Amalgam tattoos 171
American Osteopathic College
of Dermatology (AOCD) 6
Amide and ester
anesthetics 249
Aminolevulinic acid 191
Amphotericin B 138
Amyloidosis and skin 126
Amyopathic DM (ADM) 108
Androgenetic alopecia 164
Anesthesia 248
– and ergonomics 353
– ester and amide
anesthetics 248
– for biopsy 276
– in adults 249
– in pediatrics 248
– in pregnancy 249
– local anesthetics, additives
to 250
– epinephrine 250
– sodium bicarbonate 250
– local anesthetics, systemic
reactions to 251
– mechanism and
structure 248
– nerve blocks 250
– topical anesthetics 251
– tumescent anesthesia 250
Angioedema 55
Angiogenesis 266
Angiomatosis 376
Angiotensin-converting
enzyme (ACE) inhibitor 55
Antibacterials 192
Antibiotic prophylaxis 299
Antifungals 191–192
Antigen presenting cell
(APC) 18
Antihistamines 191
Antimicrobial PDT (aPDT) 204
Antimicrobials 191, 192
Antineutrophil cytoplasmic
antibody-associated
vasculitis 83
Antiparasitics 192
Antiseptics 277
Antivirals 191–192
AOCD, *see* American
Osteopathic College of
Dermatology (AOCD)
APC, *see* Antigen presenting
cell (APC)
APD, *see* Association of
Professors of Dermatology
(APD)
aPDT, *see* Antimicrobial PDT
(aPDT)
Aphthous stomatitis 171
Aplasia cutis congenita 363
Apoptosis 266
Arteriovenous malformations
(AVMs) 380
Arthropathies and
dermatologic
manifestations 124
Ash-leaf spots 381, 381
Association of Professors of
Dermatology (APD) 10, 12
Asteatotic eczema 43
– diagnostic approach of 43
– key clinical findings and
presentations of 43
– pathogenesis of 43
– pertinent facts/medical
associations of 44
– treatments of 44
AT, *see* Ataxia-Telangiectasia
(AT)
Ataxia-Telangiectasia (AT) 384
– diagnosis 384
– epidemiology and
genetics 384
– pathophysiology 384
– symptoms 384
– treatment 384
Atopic dermatitis (AD) 28, 39
– as a systemic condition 123
– diagnostic approach for 39
– key clinical findings for 39
– pathogenesis for 39
– pertinent facts or medical
associations 40
– treatments for 39
– UV therapy in 201
ATP2A2 gene 400
Atrophic glossitis 171
Audition rotations 7, 10
– expectations on 10
– planning/scheduling
audition rotations 10
Auriculotemporal nerve 234
Auto-inflammatory
disorders 372
Autoimmune and sclerosing
connective tissue disorders,
nailfold capillaroscopy
in 117
Autoimmune disorders of oral
mucosa 173
Autoinflammatory diseases 55
Autologous fat 329
Autosomal recessive
disorder 388
AVMs, *see* Arteriovenous
malformations (AVMs)

B

- Bacterial infections 135
– diagnostic approach 135
– key clinical findings 135
– pertinent facts/medical
associations 136
– treatment options 135
Barbed sutures 255
Bard-Parker Scalpel
handle 260
Basal cell carcinoma (BCC) 4,
29, 266, 310
– clinical presentation 266
– genetic alterations 267
– locally advanced 311
– pathogenesis 267
– unresectable/
metastatic 311
Base excision repair (BER) 17

- nailfold capillaroscopy (NFC) 117
 - scleroderma after cosmetic surgery 117
 - Connective tissue disorders 221
 - Connective tissue disorders, cutaneous manifestations of 105
 - collaborative approach in dermatology 109
 - cutaneous lupus erythematosus, treatment for 107
 - dermatomyositis clinical subtypes 108
 - dermatomyositis diagnostic criteria 108
 - subtypes and clinical differences 108
 - dermatomyositis histopathological findings 108
 - dermatomyositis treatment and management 108
 - relapsing polychondritis 109
 - rheumatoid arthritis 109
 - Sjogren's syndrome 109
 - systemic lupus erythematosus, dermatological aspects of 105
 - acute cutaneous lupus erythematosus 105
 - chronic cutaneous lupus erythematosus (CCLE) 107
 - subacute cutaneous lupus erythematosus 106
 - systemic lupus erythematosus, epidemiology of 105
 - Contact dermatitis (CD) 40
 - diagnostic approach for 40
 - key clinical findings in 40
 - pathogenesis for 40
 - pertinent facts or medical associations for 41
 - treatment options for 40
 - Core rotations 7
 - Cornification, disorders of 396
 - Darier disease 399
 - diagnosis 400
 - epidemiology and genetics 400
 - pathophysiology 400
 - symptoms 400
 - treatment 400
 - ichthyosis 396
 - diagnosis 396
 - epidemiology and genetics 396
 - pathophysiology 396
 - signs and symptoms 396
 - treatment 397
 - palmoplantar keratoderma (PPK) 398
 - diagnosis 398
 - epidemiology and genetics 398
 - pathophysiology 398
 - symptoms 398
 - treatment 398
 - porokeratosis 400
 - diagnosis 401
 - epidemiology and genetics 400
 - pathophysiology 400
 - symptoms 401
 - treatment 401
 - Cosmetic dermatologic surgery 412
 - Cosmetic dermatologic surgery fellowships
 - application process for 412
 - tips for applying to 414
 - Cosmetics, neurotoxin use in 319
 - COVID-19 pandemic 393
 - Cowden's syndrome 173
 - CPD, *see* Cyclobutene pyrimidine dimer (CPD)
 - Cranial nerves 234
 - CREST syndrome 146
 - CRISPR-Cas9 gene editing 18
 - Crohn's disease (CD) 102, 125, 173
 - CRS, *see* Congenital rubella syndrome (CRS)
 - Cryoglobulinemic vasculitis, types II/III 83, 84
 - Cryolipolysis 350
 - Cryopyrin-associated periodic syndromes (CAPS) 372
 - Cryotherapy (cryosurgery) 270
 - CS, *see* Chondroid syringomas (CS), Cockayne syndrome (CS)
 - cSCC, *see* Cutaneous squamous cell carcinoma (cSCC)
 - CTCL, *see* Cutaneous T-cell lymphoma (CTCL)
 - CTDs, *see* Connective tissue diseases (CTDs)
 - Curettes and comedone extractors 262
 - Curriculum vitae (CV) 3, 11
 - Cutaneous angiosarcoma 379
 - Cutaneous capillary malformations (port wine stains) 379
 - Cutaneous eruptions of the newborn 357
 - benign lesions 357
 - congenital infections 361
 - emergent 361
 - kaposiform hemangioendothelioma 362
 - purpura fulminans 362
 - sclerema neonatorum 362
 - urgent 362
 - aplasia cutis congenita 363
 - congenital hemangioma 362
 - impetigo neonatorum and staph scalded skin syndrome 363
 - segmental infantile hemangioma 362
 - Cutaneous infections 30
 - Cutaneous lichen planus 36
 - diagnostic approach for 36
 - key clinical findings in 36
 - pertinent facts or medical associations for 36
 - treatment options for 36
 - Cutaneous lupus erythematosus (CLE) 37
 - diagnostic approach for 37
 - key clinical findings in 37
 - treatment for 107
 - treatment options for 37
 - Cutaneous manifestations
 - of internal diseases 176
 - of renal disease 124
 - Cutaneous mastocytosis 405
 - Cutaneous melanoma 306
 - resectable cutaneous melanoma 306
 - unresectable/metastatic cutaneous melanoma 310
 - Cutaneous neoplasms 266
 - basal cell carcinoma (BCC) 266
 - clinical presentation 266
 - genetic alterations 267
 - pathogenesis 267
 - melanoma 266
 - clinical presentation 266
 - genetic alterations 266
 - pathogenesis 266
 - Merkel cell carcinoma 269
 - clinical presentation 269
 - genetic alterations 269
 - pathogenesis 269
 - squamous cell carcinoma (SCC) 267
 - clinical presentation 267
 - genetic alterations 268
 - pathogenesis 267
 - Cutaneous porphyrias 120
 - clinical presentations and therapies 120
 - Cutaneous squamous cell carcinoma (cSCC) 4, 311
 - resectable cutaneous squamous cell carcinoma 311
 - unresectable/metastatic cutaneous squamous cell carcinoma 311
 - Cutaneous T-cell lymphoma (CTCL) 197
 - UV therapies for 200
 - Cutis laxa 130–131, 367
 - CV, *see* Curriculum vitae (CV)
 - CVID, *see* Chronic variable immunodeficiency (CVID)
 - Cyanoacrylate embolization 346
 - Cyclobutene pyrimidine dimer (CPD) 17
 - CYLD gene 86
 - Cylindroma/spiradenoma 87–88
- ## D
- Dabska's tumor, *see* Papillary intralymphatic angioendothelioma (PILA)
 - Darier disease 399
 - diagnosis 400
 - epidemiology and genetics 400
 - pathophysiology 400
 - symptoms 400
 - treatment 400
 - DCA, *see* Deoxycholic acid (DCA)
 - DDEB, *see* Dominant dystrophic epidermolysis bullosa (DDEB)
 - DEB, *see* Dystrophic epidermolysis bullosa (DEB)
 - Dehiscence 302
 - Demelanizing agents 193, 193
 - Deoxycholic acid (DCA) 349
 - Depositional diseases and skin 126
 - Depositional disorders
 - endogenous material 222
 - foreign material 222
 - Dermal pharmacokinetics 189
 - Dermatitis 26
 - Dermatitis herpetiformis 48
 - Dermatofibroma 210
 - Dermatology applicant 9
 - successful applicant, characteristics of 9, 9
 - Dermatology Interest Group Association (DIGA) 13
 - Dermatomyositis 109, 111, 132–133, 143
 - clinical subtypes 108
 - diagnostic criteria 108
 - subtypes and clinical differences 108
 - cutaneous manifestations 143
 - histopathological findings 108

- prevalence and mechanism **143**
 - treatment and management **108**
 - Dermatopathology **411**
 - training and scope of practice for **411**
 - Dermatopathology fellowships
 - application process for **412**
 - tips for applying to **413**
 - Dermoscopy algorithms **209**
 - triage amalgamated dermoscopic algorithm (TADA) **214**
 - first step **214**
 - second step **214**
 - third step **214**
 - two-step algorithm **209**
 - first step **209**
 - second step **214**
 - Dermoscopy, clinical uses of **209**
 - Desquamative gingivitis **101, 171**
 - Diaper dermatitis **406**
 - Diffuse cutaneous systemic sclerosis **143**
 - Diffuse/bilateral pigmentary lesions **172**
 - DIGA, *see* Dermatology Interest Group Association (DIGA)
 - DiGeorge syndrome or chronic thymic aplasia **387**
 - Discoid eczema, *see* Nummular eczema
 - Discoid lupus erythematosus (DLE) **107, 166**
 - Disorders of melanocyte development (piebaldism) **365**
 - Disposable punch biopsy tools **259**
 - Disseminated intravascular coagulation **82**
 - Distal nail avulsion **291**
 - DLE, *see* Discoid lupus erythematosus (DLE)
 - Doctor of Osteopathic Medicine **8**
 - Dominant dystrophic epidermolysis bullosa (DDEB) **403**
 - Dowling–Degos disease **365**
 - Drains **262**
 - DRESS, *see* Drug rash with eosinophilia and systemic symptoms (DRESS)
 - Dressing supplies **294**
 - dressing technique **294, 295–296**
 - heal by secondary intention **294**
 - skin grafts **297**
 - stitches **295**
 - Drug rash with eosinophilia and systemic symptoms (DRESS) **70**
 - Drug-induced gingival overgrowth **173**
 - Drug-related mucosal changes **173**
 - Dyshidrotic eczema (acute palmoplantar eczema) **41**
 - diagnostic approach for **41**
 - histopathology for **41**
 - key clinical findings in **41**
 - management for **41**
 - pathogenesis for **41**
 - Dyskeratosis follicularis, *see* Darier disease
 - Dystrophic epidermolysis bullosa (DEB) **402–403**
- E**
- E/M coding, *see* Evaluation and management (E/M) coding
 - Ears, specialized instruments for **263**
 - EB, *see* Epidermolysis bullosa (EB)
 - EBS, *see* Epidermolysis bullosa simplex (EBS)
 - Echinocandins **138**
 - ECM accumulation, *see* Excessive extracellular matrix (ECM) accumulation
 - Eczema **28**
 - Eczematous disorders, approach to **39**
 - asteatotic eczema **43**
 - diagnostic approach of **43**
 - key clinical findings and presentations of **43**
 - pathogenesis of **43**
 - pertinent facts/medical associations of **44**
 - treatments of **44**
 - atopic dermatitis (AD) **39**
 - diagnostic approach for **39**
 - key clinical findings for **39**
 - pathogenesis for **39**
 - pertinent facts or medical associations **40**
 - treatments for **39**
 - contact dermatitis (CD) **40**
 - diagnostic approach for **40**
 - key clinical findings in **40**
 - pathogenesis for **40**
 - pertinent facts or medical associations for **41**
 - treatment options for **40**
 - dyshidrotic eczema (acute palmoplantar eczema) **41**
 - diagnostic approach for **41**
 - histopathology for **41**
 - key clinical findings in **41**
 - management for **41**
 - pathogenesis for **41**
 - pertinent facts/medical associations for **42**
 - treatment options for **42**
 - nummular eczema (discoid eczema) **42**
 - diagnostic approach for **42**
 - key clinical findings in **42**
 - pathogenesis for **42**
 - pertinent facts/medical associations for **42**
 - treatment options for **42**
 - stasis dermatitis **43**
 - diagnostic approach for **43**
 - key clinical findings for **43**
 - pathogenesis for **43**
 - pertinent facts/medical associations **43**
 - treatment for **43**
 - EDS, *see* Ehlers–Danlos syndrome (EDS), Eosinophilic dermatoses (EDs)
 - Ehlers–Danlos Syndrome (EDS) **129–130, 367, 368**
 - Elective rotations (third year/ fourth year) **7**
 - Electrocautery **262**
 - Electrodesiccation and curettage **270**
 - Electron beam radiotherapy **273**
 - Electronic medical record (EMR) programs **10**
 - Electronic Residency Application Service (ERAS) residency application **11**
 - components **11**
 - timeline **11**
 - Electrosurgery devices **262**
 - Elejalde's syndrome (ES) **364**
 - EMR programs, *see* Electronic medical record (EMR) programs
 - Eosinophilic dermatoses (EDs) **96, 96**
 - Eosinophilic dermatoses and pregnancy dermatoses **98**
 - Eosinophilic pustular folliculitis (EPF) **96–97**
 - EPF, *see* Eosinophilic pustular folliculitis (EPF)
 - Ephelides **171**
 - Epidermolysis bullosa (EB) **402**
 - diagnosis and management of **403**
 - types of **402**
 - Epidermolysis bullosa acquisita **48**
 - Epidermolysis bullosa simplex (EBS) **402**
 - Epigenetics **265**
 - Epinephrine **250**
 - Epithelioid
 - hemangi endothelioma **378**
 - Epithelioid hemangioma **376**
 - Eponychium **290**
 - ERAS residency application, *see* Electronic Residency Application Service (ERAS) residency application
 - Erbium **272**
 - Ergonomics, anesthesia and **353**
 - Eruptive
 - pseudoangiomatosis **393**
 - Erythema **61, 62**
 - in skin of color **62**
 - Erythema chronicum migrans **68**
 - Erythema infectiosum **392**
 - Erythema multiforme **53, 69, 171**
 - clinical manifestations and diagnostic criteria **53**
 - epidemiology/genetics **53**
 - histology **53**
 - surveillance and treatment **53**
 - Erythema nodosum **68**
 - Erythroplakia **174**
 - Erythropoietic protoporphyria **373**
 - ES, *see* Elejalde's syndrome (ES)
 - Ester and amide anesthetics **248**
 - Ester versus amide anesthetics **248**
 - Evaluation and management (E/M) coding based on medical decision making **424**
 - Code 99202 / 99212 **424**
 - Code 99203 / 99213 **424**
 - Code 99204 / 99214 **424**
 - Code 99205 / 99215 **424**
 - Excessive extracellular matrix (ECM) accumulation **115**
 - Excisional biopsy **278**
 - Extracurricular activities **6**
 - conferences **6**
 - shadowing **6**
 - volunteering **6**
 - Eyes, specialized instruments for **263**

F

Face

- layers of **240**
- lymphatic system of **238**
- Facial danger zones **240**
- fillers, safety principles for injecting **247**
- vascular danger zones **243**
- glabella area **243**
- infraorbital area **245**
- nasal area **245**
- nasolabial area **246**
- perioral area **246**
- temple area **244**
- Facial nerve
- distribution **235**
- frontal branch of **241**
- marginal mandibular and cervical branches of **243**
- zygomatic branch of **242**
- Facial nerve danger zones **240**
- mandible, border of **243**
- temple/lateral brow area **241**
- zygomatic eminence, region lateral to **242**
- Facial soft tissue layers **240**
- Familial Mediterranean fever (FMF) **372**
- Fat reduction, noninvasive localized **349**
- cryolipolysis **350**
- high-intensity focused ultrasound **350**
- hyperthermic laser lipolysis **350**
- injections **349**
- radiofrequency (RF) **350**
- FDE, *see* Fixed drug eruption (FDE)
- FDH, *see* Focal dermal hypoplasia (FDH)
- Fellowship application **413**
- cosmetic dermatologic surgery fellowship, tips for applying to **414**
- dermatopathology fellowship, tips for applying to **413**
- general advice for **413**
- micrographic surgery and dermatologic oncology fellowship, tips for applying to **413**
- pediatric dermatology fellowship, tips for applying to **414**
- Fellowships, dermatology **411, 414**
- Accreditation Council for Graduate Medical Education (ACGME)-approved fellowships **411**

- dermatopathology fellowship **411**
- micrographic surgery and dermatologic oncology (MSDO) fellowship **411**
- pediatric dermatology fellowship **412**
- non-Accreditation Council for Graduate Medical Education (non-ACGME)-accredited fellowships **412**
- FGF, *see* Fibroblast growth factor (FGF)
- Fibroblast growth factor (FGF) **266**
- Fibrofolliculoma **86–87**
- Fibrosis **115**
- connective tissue diseases and sclerosing disorders **116**
- cancer risk in **116**
- nailfold capillaroscopy (NFC) **117**
- scleroderma after cosmetic surgery **117**
- sclerosing disorders in dermatology **115**
- cellular mechanisms of fibrosis **116**
- epidemiology and clinical relevance **115**
- pathophysiological insights **115**
- rare scleroderma-like disorders **116**
- Fibrous tumors **227**
- Filaggrin gene (FLG) codes **39**
- Finasteride **193**
- Fissured tongue **171**
- Fixed drug eruption (FDE) **70**
- Fixed drug reaction **53**
- clinical manifestations and diagnostic criteria **53**
- epidemiology/genetics **53**
- histology **53**
- surveillance and treatment **54**
- Flaps **285, 287**
- FLG codes, *see* Filaggrin gene (FLG) codes
- 5-Fluorouracil **270**
- FMF, *see* Familial Mediterranean fever (FMF)
- Focal dermal hypoplasia (FDH) **369**
- Follicular adnexal tumors **226**
- Follicular unit extraction **353**
- Follicular unit transplantation (FUT) **352**
- graft creation from **353**
- Folliculitis decalvans/dissecting cellulitis **166**
- Forceps **261**
- Fordyce's granules **171**

- Foreign body granuloma **103**
- Fox curette **262**
- Fungal infections **137, 138**
- diagnostic approach **138**
- key clinical findings **137**
- pertinent facts/medical associations **138**
- treatment options **138**
- FUT, *see* Follicular unit transplantation (FUT)

G

- Gardner's syndrome **173**
- Gene therapy **18**
- Genetic/syndromic manifestations in oral mucosa **173**
- Genodermatoses **222**
- Genodermatoses/inherited disorders
- of connective tissue **367**
- Buschke–Ollendorf syndrome **369**
- congenital contractural arachnodactyly (CCA) or Beals syndrome **368**
- cutis laxa/generalized elastolysis **367**
- Ehlers–Danlos syndrome (EDS) **367, 368**
- focal dermal hypoplasia (FDH) or Goltz syndrome **369**
- infantile systemic hyalinosis (ISH)/juvenile hyaline fibromatosis (JHF) **369**
- lipoid proteinosis **369**
- Marfan syndrome **368**
- osteogenesis imperfecta (OI) or brittle bone disease **367**
- pseudoxanthoma elasticum (PXE) **367**
- restrictive dermopathy **369**
- stiff skin syndrome (SSS) or congenital fascial dystrophy (CFD) **370**
- of pigmentation **364**
- Dowling–Degos disease **365**
- Elejalde's syndrome (ES) **364**
- Griscelli's syndrome (GS) **364**
- Hermansky–Pudlak syndrome (HPS) **365**
- hypo-/depigmentation **364**
- lentiginoses syndromes **366**
- McCune–Albright syndrome **365**
- melanocyte development, disorders of **365**
- silver hair syndromes **364**
- Waardenburg's syndrome (WS) hyperpigmentation **365**
- Geographic tongue **171**
- Gestational pemphigoid **97**
- Gianotti–Crosti syndrome **393**
- Giant cell (temporal) arteritis **84**
- Glabella area **243**
- Glandular **226**
- Glucocorticoids **189, 190**
- Goltz syndrome **369**
- Grades **3**
- honor societies **4**
- preclinical medical school examinations **3**
- rotation grading and examinations **3**
- standardized medical licensing examinations (USMLE/NBOME) **3**
- USMLE Step 1 and/or COMLEX Level 1, preparing for **3**
- USMLE Step 2/COMLEX Level 2 **4**
- Gradle scissors **260**
- Grafts **288**
- Granular cell tumors **171**
- Granuloma annulare **103**
- Granulomatosis with polyangiitis **173**
- Granulomatous and histiocytic disease **100**
- autoimmune **100**
- infectious **102**
- inflammatory **103**
- neoplasms **103**
- reactions **103**
- Granulomatous dermatoses **222**
- Granulomatous diseases, epidemiological information for **101**
- Great auricular nerve **234**
- Griscelli's syndrome (GS) **89, 364**
- Griseofulvin **138**
- Group practice **421**
- GS, *see* Griscelli's syndrome (GS)

H

- HA, *see* Hyaluronic acid (HA)
- Hair **23**
- growth cycle **24**
- structure **23**

- types of 24
- Hair disorders 163, 163
 - nonscarring alopecia 163
 - scarring alopecia 166
- Hair follicle tumors, examples of 86
- Hair growth, drugs affecting 193
- Hair removal endpoints 340
- Hair transplantation 352
 - anesthesia and ergonomics 353
 - consult 352
 - donor harvesting 352
 - follicular unit extraction 353
 - follicular unit transplantation (FUT) 352
 - follicular unit transplantation (FUT), graft creation from 353
 - graft placement 353
 - hairline design 353
 - postoperative care and growth 354
 - recipient site creation 353
- Hairy tongue 171
- Hand-operated razor blades 259
- Hand–foot–mouth disease 394
- Hansen's disease 102
- HDCTs, *see* Heritable disorders of the connective tissues (HDCTs)
- HDR, *see* Homology-directed repair (HDR)
- Head and neck
 - motor innervation of 233
 - sensory innervation of 233
 - venous system of 238
- Hedgehog signaling pathway inhibitors (vismodegib, sonidegib) 271
- Hemangioma 376
- Hematologic causes 82
 - disseminated intravascular coagulation 82
 - heparin-induced thrombocytopenia/thrombosis 82
- Hematoma 302, 303
- Hemostasis 278
 - methods of 279
- Hemostats 261
- Henle's layer 23
- Henoch–Schonlein purpura/IgA vasculitis 83
- Heparin-induced thrombocytopenia/thrombosis 82
- Hereditary dyschromatoses 365
- Hereditary hemorrhagic telangiectasia 173
- Heritable disorders of the connective tissues (HDCTs) 129
- Hermansky–Pudlak syndrome (HPS) 365
- Herpangina 394
- Herpes simplex virus (HSV) 30
- Herpes zoster 394
- HGPS, *see* Hutchinson–Gilford progeria (HGPS)
- Hidradenitis suppurativa 119
- HIES, *see* Hyperimmunoglobulin E syndrome (HIES)
- High-intensity focused ultrasound 350
- High-yield arterial supplies 234
- High-yield dermatopathology differentials by histologic category 221
- Histiocytic 223
- Histoplasmosis 102
- Homology-directed repair (HDR) 17
- Honor societies 4
- Horizontal mattress stitch 279
- HPS, *see* Hermansky–Pudlak syndrome (HPS)
- HPV, *see* Human papillomavirus (HPV)
- HSA, *see* Human serum albumin (HSA)
- HSV, *see* Herpes simplex virus (HSV)
- Human papillomavirus (HPV) 30
- Human serum albumin (HSA) 322
- Hutchinson–Gilford progeria (HGPS) 389
- Huxley's layer 23
- Hyaluronic acid (HA) 325
- Hydroa vacciniforme 405
- Hyperimmunoglobulin E syndrome (HIES) 387
- Hyperpigmentation disorders 90, 90
- Hyperthermic laser lipolysis 350
- Hypo-/depigmentation 364
- Hyponychium 290
- Hypopigmentation disorders 88, 89
- I
 - IBD, *see* Inflammatory bowel disease (IBD)
 - Ichthyosis 396
 - diagnosis 396
 - epidemiology and genetics 396
 - pathophysiology 396
 - signs and symptoms 396
 - treatment 397
- ICP, *see* Intrahepatic cholestasis of pregnancy (ICP)
- IgA deficiency 388
- Imiquimod 191, 270
- Immune thrombocytopenic purpura 82
- Immunoglobulin deficiencies 388, 388
- Immunology 18
- Immunomodulatory agents 194, 194
- Impetigo neonatorum and staph scalded skin syndrome 363
- Implantable cardioverter-defibrillators and pacemakers 301
- Incisional biopsy 278
- Infantile systemic hyalinosis (ISH) 369
- Infections 223
- Infectious disorders 135
 - bacterial infections 135
 - diagnostic approach 135
 - key clinical findings 135
 - pertinent facts/medical associations 136
 - treatment options 135
 - fungal infections 137, 138
 - diagnostic approach 138
 - key clinical findings 137
 - pertinent facts/medical associations 138
 - treatment options 138
 - parasitic infections 138
 - diagnostic approach 139
 - key clinical findings 138
 - pertinent facts/medical associations 139
 - treatment options 139
 - viral infections 136, 136
 - diagnostic approach 136
 - key clinical findings 136
 - pertinent facts/medical associations 137
 - treatment options 136
- Infectious insults to oral mucosa 173
- Inflammatory bowel disease (IBD) 102
 - and cutaneous manifestations 125
- Inflammatory disorders 224
- Infraorbital area 245
- Injections 349
- Interface reactions 224
- Interrupted buried dermal stitch 279
- Interview 12
 - after 13
- day of 13
- preparing for 12
- responding to invite of 12
- Intraepidermal disorders 46
 - paraneoplastic pemphigus 48
 - pemphigus vegetans 48
 - pemphigus vulgaris 46
- Intrahepatic cholestasis of pregnancy (ICP) 98
- Intrinsic aging and extrinsic aging 317
- Iris scissors 260
- ISH, *see* Infantile systemic hyalinosis (ISH)
- J
 - Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway 19
 - JDM, *see* Juvenile DM (JDM)
 - JEB, *see* Junctional epidermolysis bullosa (JEB)
 - JHF, *see* Juvenile hyaline fibromatosis (JHF)
 - Job syndrome 387
 - Junctional epidermolysis bullosa (JEB) 402–403
 - Juvenile DM (JDM) 108
 - Juvenile hyaline fibromatosis (JHF) 369
 - Juvenile plantar dermatosis 406
 - Juvenile spring eruption 404
- K
 - Kaposiform hemangioendothelioma 362, 377
 - Kaposi's sarcoma (KS) 378
 - Kawasaki disease 84
 - Keratolytics 191
 - Keratosis follicularis, *see* Darier disease
 - Kindler EB 402–403
 - KS, *see* Kaposi's sarcoma (KS)
- L
 - Labial melanocytic macules 171
 - LAD, *see* Leukocyte adhesion deficiency (LAD)
 - Langerhans cell histiocytosis 103
 - Langer's lines 233
 - Large vessel 84
 - giant cell (temporal) arteritis 84
 - Takayasu arteritis 84

- Laser 271, 334
- ablative lasers 272
 - and radiofrequency ablation 346
 - cyanoacrylate embolization 346
 - applications in dermatology 335
 - ablative resurfacing lasers 336
 - energy devices 336
 - laser hair removal 335
 - light devices 335
 - pigmented lesions and tattoos, treatment of 335
 - vascular lesions, treatment of 335
 - physics 334
 - laser parameters 334
 - nomenclature 334
 - selective photothermolysis 334
 - vascular lasers 272
- Laser endpoints 338
- ablative laser resurfacing endpoints 340
 - hair removal endpoints 340
 - nevus of Ota endpoints 339
 - nonablative laser resurfacing endpoints 340
 - tattoo removal endpoints 339
 - vascular endpoints 338
 - lentiginous endpoints 339
- Laser therapy, complications of 336
- Lateral longitudinal nail biopsy 292
- Laugier–Hunziker syndrome (LHS) 91, 366
- Leg veins, sclerotherapy and treatment of 342
- pathophysiology 342
 - telangiectasias and reticular veins, techniques for treating 342
 - compression 344
 - laser and radiofrequency ablation 346
 - sclerotherapy 344
- Lentiginous endpoints 339
- Lentiginoses syndromes 366
- LEOPARD syndrome 366
- Leprosy 102
- Letters of recommendation (LORs) 7, 9, 12
- Leukocyte adhesion deficiency (LAD) 388
- Leukocytoclastic vasculitis, see Small vessel
- Leukoplakia 174
- LHS, *see* Laugier–Hunziker syndrome (LHS)
- Lichen nitidus 52
- clinical manifestations, diagnostic criteria 52
 - epidemiology/genetics 52
 - histology 52
 - surveillance and treatment 52
- Lichen planopilaris (LPP) 166
- Lichen planus 50
- clinical manifestations and diagnostic criteria 50
 - epidemiology/genetics 50
 - histology 50
 - surveillance and treatment 50
- Lichen planus of the nail 168
- Lichen simplex 41
- diagnostic approach for 42
 - key clinical findings in 41
 - pathogenesis for 41
 - pertinent facts/medical associations for 42
 - treatment options for 42
- Lichen striatus 52
- clinical manifestations and diagnostic criteria 52
 - epidemiology/genetics 52
 - histology 52
 - surveillance and treatment 52
- Lichenoid and interface dermatoses 50, 50
- erythema multiforme 53
 - clinical manifestations and diagnostic criteria 53
 - epidemiology/genetics 53
 - histology 53
 - surveillance and treatment 53
 - fixed drug reaction 53
 - clinical manifestations and diagnostic criteria 53
 - epidemiology/genetics 53
 - histology 53
 - surveillance and treatment 54
 - pityriasis lichenoides et varioliformis acuta 52
 - clinical manifestations and diagnostic criteria 53
 - epidemiology/genetics 52
 - histology 53
 - surveillance and treatment 53
- Lichenoid drug eruption 50
- clinical manifestations and diagnostic criteria 52
 - epidemiology/genetics 50
 - histology 52
 - surveillance and treatment 52
- Lidocaine 249
- Light devices 335
- Limited cutaneous systemic sclerosis 146
- clinical manifestations, diagnostic criteria 49
- Linear immunoglobulin A 49
- Lipoid proteinosis 369
- Lipophilic drugs 189
- Liposuction and fat reduction 347
- noninvasive localized fat reduction 349
 - cryolipolysis 350
 - high-intensity focused ultrasound 350
 - hyperthermic laser lipolysis 350
 - injections 349
 - radiofrequency (RF) 350
 - tumescent liposuction 347
- Lisch nodules 382, 383
- Livedoid vasculopathy 84, 85
- Local anesthetics
- additives to 250
 - epinephrine 250
 - sodium bicarbonate 250
 - systemic reactions to 251
- LORs, *see* Letters of recommendation (LORs)
- LPP, *see* Lichen planopilaris (LPP)
- Lupus erythematosus 173
- Lymphangioma 376
- Lymphatic malformations 379
- Lymphatic system of face 238
- ## M
- MAC, *see* Microcystic adnexal carcinoma (MAC)
- Macrophage activation syndrome 372
- Major histocompatibility complex (MHC) 18
- Malformations 225
- Malignant melanoma (MM) 4
- Malignant tumors 228, 378
- cutaneous angiosarcoma 379
 - epithelioid hemangioendothelioma 378
- Marfan syndrome (MFS) 129–130, 368
- MC1 R variants, *see* Melanocortin 1 receptor (MC1R) variants
- McCune–Albright syndrome 365
- MDM, *see* Medical decision making (MDM)
- Measles 392
- Median nerve 234
- Median rhomboid glossitis 171
- Medical decision making (MDM), evaluation and management (E/M) coding based on 424
- Code 99202 / 99212 424
 - Code 99203 / 99213 424
 - Code 99204 / 99214 424
 - Code 99205 / 99215 424
- Medical licensing examinations 9
- Comprehensive Osteopathic Medical Licensing Examination (COMLEX) 9
 - examination scores 10
 - United States Medical Licensing Examination 9
- Medium vessel 83
- Kawasaki disease (mucocutaneous lymph node syndrome) 84
 - skin-limited cutaneous polyarteritis nodosa 84
- Melanizing/demelanizing agents 193
- Melanocortin 1 receptor (MC1R) variants 266
- Melanocytes and pigmentation 21
- Melanocytic lesions, features of 211
- Melanocytic tumors 227, 229
- Melanoma 29, 266
- clinical presentation 266
 - genetic alterations 266
 - pathogenesis 266
- Melanoma and nonmelanoma skin cancers, oncologic agents in dermatology for 306
- basal cell carcinoma 310
 - cutaneous melanoma 306
 - cutaneous squamous cell carcinoma 311
 - Merkel cell carcinoma 311
- Melanonychia striata 169
- Melasma 90, 120
- MEN type 2B, *see* Multiple endocrine neoplasia (MEN) type 2B
- Menkes' disease 373
- Mentor, finding 418
- Mentorship 3, 9
- addressing racial, ethnic, and gender disparities 417
 - defining 416
 - impact in professional development 416
- Merkel cell carcinoma 269, 311
- clinical presentation 269
 - genetic alterations 269
 - pathogenesis 269
 - resectable merkel cell carcinoma 311
 - unresectable/metastatic merkel cell carcinoma 311

- Metabolic disorders in dermatology 121
- early detection and management, role of dermatologists in 121
 - diet and lifestyle interventions, impact of 121
 - preventive aspects and patient education 121
- Metabolic syndrome (MetS) 119
- acanthosis nigricans. 120
 - acne vulgaris, inflammatory link in 119
 - cutaneous porphyrias 120
 - clinical presentations and therapies 120
 - hidradenitis suppurativa 119
 - melasma 120
 - psoriasis 119
- Metabolic/nutritional disorders 373
- MFS, *see* Marfan Syndrome (MFS)
- MHC, *see* Major histocompatibility complex (MHC)
- Microcannulas 348
- Microcystic adnexal carcinoma (MAC) 87–88
- Micrographic surgery and dermatologic oncology (MSDO) fellowship 411
- application process for 411
 - tips for applying to 413
 - training and scope of practice for 411
- Microscope
- anatomy of 217
 - how to use 218
 - strengths and limitations of 217
- Minoxidil 193
- Miscellaneous tumors/lesions 227
- Mismatch repair (MMR) 17
- Mismatched relationship, pitfalls of 417
- MM, *see* Malignant melanoma (MM)
- MMR, *see* Mismatch repair (MMR)
- MMS, *see* Mohs micrographic surgery (MMS)
- Modifier codes for evaluation, management, and procedures 426
- Modifier 24 426
 - Modifier 25 427
 - Modifier 51 427
 - Modifier 58 427
 - Modifier 59 427
- Modifier 79 427
- Mohs micrographic surgery (MMS) 283, 286
- indications/contraindications for 283
 - preoperative considerations in 284
 - procedural steps of 285
- Molecular biology 17
- gene therapy 18
- Monobenzone 193
- Morbilliform drug eruption 70
- Morsicatio buccarum 171
- Motor innervation of head and neck 233
- MSDO fellowship, *see* Micrographic surgery and dermatologic oncology (MSDO) fellowship
- Mucinoses and skin 126
- Mucocele 171
- Mucocutaneous lymph node syndrome 84
- Mucosal disease, infectious causes of 174
- Mucosal disorders 171
- benign conditions of oral mucosa 171
 - genetic/syndromic manifestations in oral mucosa 173
 - infectious insults to the oral mucosa 173
 - inflammatory disorders of oral mucosa 171
 - allergic disorders of the oral mucosa 173
 - autoimmune disorders of oral mucosa 173
 - drug-related mucosal changes 173
 - mucosal pigmentary lesions 171
 - premalignant and malignant conditions of oral mucosa 174
 - traumatic mucosal lesions 171
- Mucosal pigmentary lesions 171
- Mucous membrane pemphigoid 173
- Muir–Torre syndrome 17
- Multiple endocrine neoplasia (MEN) type 2B 173
- Mycobacterium tuberculosis 102
- N**
- Nail 24, 290
- anatomy of 290
 - and hair changes 124
 - function 25
 - innervation and vascular supply 291
 - specialized instruments for 263
 - structure 24
 - surgery 291
 - nail biopsies 292
 - nail plate avulsion 291
 - postoperative care and complications of 293
- Nail bed 290
- Nail bed biopsy 292
- Nail disorders 167, 167
- Nail matrix 290
- Nail matrix biopsy 292
- Nail psoriasis 167
- Nailfold capillaroscopy (NFC) 117
- Nasal area 245
- Nasolabial area 246
- National Residency Matching Program (NRMP) 3, 5
- NDs, *see* Neutrophilic dermatoses (NDs)
- Necrosis 302
- Needle driver 261
- NEH, *see* Neutrophilic eccrine hidradenitis (NEH)
- Neoplastic dermatology pathways 265
- cancer, hallmarks of 265
 - angiogenesis 266
 - apoptosis 266
 - cancer genes 265
 - cell cycle 265
 - cutaneous neoplasms 266
 - basal cell carcinoma (BCC) 266
 - melanoma 266
 - Merkel cell carcinoma 269
 - squamous cell carcinoma (SCC) 267
- Nephrogenic systemic fibrosis (NSF) 124
- NER, *see* Nucleotide excision repair (NER)
- Nerve blocks 250
- Nerve damage 301
- Neural tumors 228
- Neurocutaneous disorders 140
- acquired 144
 - dermatomyositis 143
 - cutaneous manifestations 143
 - prevalence and mechanism 143
 - inherited 141
 - neurofibromatosis type 1 140
 - cutaneous manifestations. 140
 - prevalence and genetics 140
 - neurofibromatosis type 2 140
 - cutaneous manifestations. 140
 - prevalence and genetics 140
 - scleroderma 143
 - localized cutaneous manifestations 143
 - prevalence and mechanism 143
 - systemic cutaneous manifestations 143
 - systemic lupus erythematosus 140
 - cutaneous manifestations 143
 - prevalence and mechanism 140
 - tuberous sclerosis complex (TSC) 140
 - cutaneous manifestations 140
 - prevalence and mechanism 140
 - tuberous sclerosis complex (TSC) 140
 - cutaneous manifestations 140
 - prevalence and genetics 140
- Neurocutaneous syndromes and tumor syndromes 381
- Ataxia-Telangiectasia (AT) 384
 - diagnosis 384
 - epidemiology and genetics 384
 - pathophysiology 384
 - symptoms 384
 - treatment 384
 - neurofibromatosis 382
 - diagnosis 383
 - epidemiology and genetics 382
 - pathophysiology 382
 - symptoms 382
 - treatment 383
 - Sturge–Weber syndrome (SWS) 383
 - diagnosis 383
 - epidemiology and genetics 383
 - pathophysiology 383
 - symptoms 383
 - treatment 383
 - tuberous sclerosis complex 381
 - diagnosis 381
 - epidemiology and genetics 381
 - pathophysiology 381
 - symptoms 381
 - treatment 381
- Neurodermatitis, *see* Lichen simplex
- Neurofibromatosis 382
- diagnosis 383

- epidemiology and genetics **382**
 - pathophysiology **382**
 - symptoms **382**
 - treatment **383**
 - type 1 **140**
 - cutaneous manifestations. **140**
 - prevalence and genetics **140**
 - type 2 **140**
 - cutaneous manifestations. **140**
 - prevalence and genetics **140**
 - Neurotoxin **319**
 - botulinum toxin **319**
 - choice in formulation **321**
 - complications and management **323**
 - contraindications and considerations **323**
 - in cosmetics **319**
 - new drug discussion **322**
 - use in cosmetics **319**
 - Neutrophilic dermatoses (NDs) **94, 94**
 - Neutrophilic eccrine hidradenitis (NEH) **94, 96**
 - Nevus of Ota endpoints **339**
 - NFC, *see* Nailfold capillaroscopy (NFC)
 - NHEJ, *see* Nonhomologous end joining (NHEJ)
 - Nicotine stomatitis **189**
 - No home dermatology program **7**
 - Non-Accreditation Council for Graduate Medical Education (non-ACGME)-accredited fellowships **412–413**
 - cosmetic dermatologic surgery **412**
 - cosmetic dermatologic surgery fellowships, application process for **412**
 - fellowship application **413**
 - cosmetic dermatologic surgery fellowship, tips for applying to **414**
 - dermatopathology fellowship, tips for applying to **413**
 - general advice for **413**
 - micrographic surgery and dermatologic oncology fellowship, tips for applying to **413**
 - pediatric dermatology fellowship, tips for applying to **414**
 - Non-steroidal anti-inflammatory drugs (NSAIDs) **297**
 - Nonablative laser resurfacing endpoints **340**
 - Nonabsorbable sutures **255**
 - Nonhomologous end joining (NHEJ) **17**
 - Noninvasive localized fat reduction **349**
 - cryolipolysis **350**
 - high-intensity focused ultrasound **350**
 - hyperthermic laser lipolysis **350**
 - injections **349**
 - radiofrequency (RF) **350**
 - Nonmelanoma skin cancers, nonsurgical options for **270, 273**
 - cryotherapy (cryosurgery) **270**
 - electrodesiccation and curettage **270**
 - lasers **271**
 - ablative lasers **272**
 - vascular lasers **272**
 - photodynamic therapy **271**
 - procedures/indications and advantages **273**
 - radiation therapy **272**
 - brachytherapy **273**
 - electron beam radiotherapy **273**
 - superficial radiation therapy **272**
 - targeted systemic therapy **271**
 - hedgehog signaling pathway inhibitors **271**
 - programmed-death receptor-1 inhibitors **271**
 - topical chemotherapeutic agents **270**
 - 5-fluorouracil **270**
 - imiquimod **270**
 - Nonmelanoma skin cancers, oncologic agents in dermatology for **306**
 - basal cell carcinoma **310**
 - cutaneous melanoma **306**
 - cutaneous squamous cell carcinoma **311**
 - Merkel cell carcinoma **311**
 - Nonscarring alopecia **163**
 - NRMP, *see* National Residency Matching Program (NRMP)
 - NSAIDs, *see* Non-steroidal anti-inflammatory drugs (NSAIDs)
 - NSF, *see* Nephrogenic systemic fibrosis (NSF)
 - Nucleotide excision repair (NER) **17**
 - Nummular eczema **42**
 - diagnostic approach for **42**
 - key clinical findings in **42**
 - pathogenesis for **42**
 - pertinent facts/medical associations for **42**
 - treatment options for **42**
- ## O
- OCA, *see* Oculocutaneous albinism (OCA)
 - Oculocutaneous albinism (OCA) **89, 364, 364**
 - OI, *see* Osteogenesis imperfecta (OI)
 - Omenn syndrome **387**
 - Oncogenes **265**
 - Oncologic agents in dermatology for melanoma and nonmelanoma skin cancers **306**
 - basal cell carcinoma **310**
 - cutaneous melanoma **306**
 - cutaneous squamous cell carcinoma **311**
 - Merkel cell carcinoma **311**
 - Onychodermal band **290**
 - Onychomycosis **168**
 - Oral cavity, specialized instruments for **263**
 - Oral lichen planus **171**
 - Oral melanocytic nevi **171**
 - Oral mucosa
 - allergic disorders of **173**
 - autoimmune disorders of **173**
 - benign conditions of **171**
 - drug-related mucosal changes **173**
 - genetic/syndromic manifestations in **173**
 - infectious insults to **173**
 - inflammatory disorders of **171**
 - malignancy in **175**
 - premalignant and malignant conditions of **174**
 - Orofacial granulomatosis **173**
 - Osteogenesis imperfecta (OI) **367**
 - Ota endpoints, nevus of **339**
 - Overlap syndromes **108**
- ## P
- Palmoplantar keratoderma (PPK) **398**
 - diagnosis **398**
 - epidemiology and genetics **398**
 - pathophysiology **398**
 - symptoms **398**
 - treatment **398**
 - Panniculitis **224**
 - Papillary intralymphatic angioendothelioma (PILA) **377, 377**
 - Papulosquamous disorders **35, 225**
 - cutaneous lichen planus **36**
 - diagnostic approach for **36**
 - key clinical findings in **36**
 - pertinent facts or medical associations for **36**
 - treatment options for **36**
 - cutaneous lupus erythematosus (CLE) **37**
 - diagnostic approach for **37**
 - key clinical findings in **37**
 - treatment options for **37**
 - pityriasis rosea **36**
 - diagnostic approach for **37**
 - key clinical findings in **36**
 - pertinent facts or medical associations for **37**
 - treatment options for **37**
 - psoriasis **35**
 - diagnostic approach for **35**
 - key clinical findings in **35, 35**
 - pertinent facts or medical associations for **35**
 - treatment options for **35**
 - seborrheic dermatitis **35**
 - diagnostic approach for **35**
 - key clinical findings in **35**
 - pertinent facts or medical associations for **36**
 - treatment options for **36**
 - Paraneoplastic pemphigus **48**
 - Parasitic infections **138**
 - diagnostic approach **139**
 - key clinical findings **138**
 - pertinent facts/medical associations **139**
 - treatment options **139**
 - Paronychia **169**
 - Paronychium **290**
 - Partial nail avulsion **291**
 - Pediatric dermatology **412**
 - training and scope of practice for **412**
 - Pediatric dermatology fellowships
 - application process for **412**
 - tips for applying to **414**
 - Pediatric rashes **402**
 - acropustulosis of infancy **405**
 - cutaneous mastocytosis **405**
 - diaper dermatitis **406**
 - epidermolysis bullosa (EB) **402**
 - diagnosis and management of **403**
 - types of **402**

- juvenile plantar dermatosis **406**
- selected photosensitive conditions **404**
- actinic prurigo **404**
- hydroa vacciniforme **405**
- juvenile spring eruption **404**
- Pembrolizumab **271**
- Pemphigus disorders **47**
- Pemphigus foliaceus **46**
- Pemphigus vegetans **48**
- Pemphigus vulgaris **46, 173**
- Periodic fever syndromes (PFS) **372**
- Perioral area **246**
- Personal statement (PS) **11**
- Peutz–Jeghers syndrome (PJS) **366**
- PFS, *see* Periodic fever syndromes (PFS)
- PG, *see* Pyoderma gangrenosum (PG)
- Pharmacology **189**
- actinic keratosis (AK) **191**
- antihistamines **191**
- antimicrobials **191, 192**
- botulinum toxins (BTX) **193**
- immunomodulatory agents (nonsteroidal) **194**
- dermal pharmacokinetics **189**
- dermatological pharmacology **189**
- hair growth, drugs affecting **193**
- keratolytics **191**
- melanizing/demelanizing agents **193**
- topical retinoids **190**
- topical steroids (glucocorticoids) **189**
- topical therapy, principles of **189**
- topical vitamin D analogs **190**
- Phenylketonuria **336**
- Photodynamic therapy **271**
- Photosensitive conditions, selected **404**
- actinic prurigo **404**
- hydroa vacciniforme **405**
- juvenile spring eruption **404**
- Physical and sexual abuse **147**
- Piebaldism **89**
- Piffard curette **262**
- Pigmentary disorder **88**
- hyperpigmentation disorders **90, 90**
- hypopigmentation disorders **88, 89**
- Pigmented lesions and tattoos, treatment of **335**
- Pigmented purpuric dermatoses (capillaritis) **82**
- PIH, *see* Postinflammatory hyperpigmentation (PIH)
- PILA, *see* Papillary intralymphatic angioendothelioma (PILA)
- Pilomatricoma **86–87**
- Pityriasis lichenoides et varioliformis acuta **52**
- clinical manifestations and diagnostic criteria **53**
- epidemiology/genetics **52**
- histology **53**
- surveillance and treatment **53**
- Pityriasis rosea **36, 393**
- diagnostic approach for **37**
- key clinical findings in **36**
- pertinent facts or medical associations for **37**
- treatment options for **37**
- PJS, *see* Peutz–Jeghers syndrome (PJS)
- Platelet-related causes **82**
- immune thrombocytopenic purpura **82**
- thrombotic thrombocytopenic purpura (TTP) **82**
- Plexiform neurofibromas (PNs) **140**
- PLLA, *see* Poly-L-lactic acid (PLLA)
- PMMA, *see* Polymethyl methacrylate (PMMA)
- PNS, *see* Plexiform neurofibromas (PNs)
- Poikiloderma **389, 390**
- Poliglecaprone 25 **255**
- Poly-L-lactic acid (PLLA) **328**
- Polyenes **138**
- Polymethyl methacrylate (PMMA) **328**
- Polymorphous eruption of pregnancy (PEP), *see* Pruritic and urticarial papules and plaques of pregnancy (PUPPP)
- Porokeratosis **400**
- diagnosis **401**
- epidemiology and genetics **400**
- pathophysiology **400**
- symptoms **401**
- treatment **401**
- Porphyria cutanea tarda **48**
- Port wine stains **379**
- Postinflammatory hyperpigmentation (PIH) **91**
- PPK, *see* Palmoplantar keratodermas (PPK)
- Preclinical medical school examinations **3**
- Pregnancy dermatoses **94, 97–98**
- Premalignant and malignant conditions of oral mucosa **174**
- Premature aging syndromes **388**
- Bloom syndrome or congenital telangiectatic erythema **389**
- Cockayne syndrome (CS) **389**
- Hutchinson–Gilford progeria (HGPS) **389**
- Rothmund–Thomson syndrome (RTS) **389**
- trichothiodystrophy (TTD) **389**
- Werner syndrome **389**
- xeroderma pigmentosum (XP) **388**
- Primary immunodeficiency disorders with cutaneous findings **387**
- chronic granulomatous disease (CGD) **387**
- chronic variable immunodeficiency (CVID) **388**
- DiGeorge syndrome or chronic thymic aplasia **387**
- hyperimmunoglobulin E syndrome (HIES) or job syndrome **387**
- IgA deficiency **388**
- immunoglobulin deficiencies **388, 388**
- leukocyte adhesion deficiency (LAD) **388**
- Omenn syndrome **387**
- severe combined immunodeficiency (SCID) **387**
- WHIM syndrome **388**
- Wiskott–Aldrich syndrome **387**
- X-linked agammaglobulinemia (XLA) **388**
- Private practice **421**
- group practice **421**
- solo practice **421**
- Proactive menteeship **416**
- Programmed-death receptor-1 inhibitors (cemiplimab, pembrolizumab) **271**
- Prolonged suture implantation **255**
- Proximal nail avulsion **292**
- Pruritic and urticarial papules and plaques of pregnancy (PUPPP) **97**
- Pruritus **124**
- PS, *see* Personal statement (PS)
- Pseudomonas aeruginosa **168**
- Pseudoxanthoma elasticum (PXE) **367**
- Psoralen **193**
- Psoriasis **28, 35, 119, 167, 198**
- diagnostic approach for **35**
- key clinical findings in **35**
- pertinent facts or medical associations for **35**
- treatment options for **35**
- UV therapy in managing **198**
- clinical outcomes **199**
- comparative efficacy of PUVA and NB-UVB **199**
- Psoriatic arthritis (PsA) **125**
- Publishing/presenting research **4**
- Punch **277**
- PUPPP, *see* Pruritic and urticarial papules and plaques of pregnancy (PUPPP)
- Purpura fulminans **82, 362**
- Purpuras and vasculitis/vasculopathy **82**
- hematologic causes **82**
- disseminated intravascular coagulation **82**
- heparin-induced thrombocytopenia/thrombosis **82**
- pigmented purpuric dermatoses (capillaritis) **82**
- platelet-related causes **82**
- immune thrombocytopenic purpura **82**
- thrombotic thrombocytopenic purpura (TTP) **82**
- purpura fulminans **82**
- senile/actinic purpura **82**
- vasculitis **83**
- large vessel **84**
- medium vessel **83**
- small vessel **83**
- small/medium vessel (mixed) **83**
- variable vessel **84**
- vasculopathy/retiform purpura **84**
- calciphylaxis **85**
- cholesterol embolization **85**
- livedoid vasculopathy **84**
- PXE, *see* Pseudoxanthoma elasticum (PXE)
- Pyoderma gangrenosum (PG) **94–95**
- Pyogenic granulomas **171**

Q

QBanks, *see* Question banks (QBanks)
 Question banks (QBanks) 4

R

RA, *see* Rheumatoid arthritis (RA)
 Radial nerve 234
 Radiation therapy 272
 – brachytherapy 273
 – electron beam radiotherapy 273
 – superficial radiation therapy 272
 Radiofrequency (RF) 350
 RDEB, *see* Recessive dystrophic epidermolysis bullosa (RDEB)
 Reaction patterns 219
 Recessive dystrophic epidermolysis bullosa (RDEB) 403
 Relapsing polychondritis 109, 111
 Relaxed skin tension lines 233
 Research 4
 – finding 4
 – publishing/presenting research 4
 – types of 4
 Research years 5
 – dual MD/PhD, DO/PhD degrees 6
 – traditional research year 5
 Residency application 7
 Restrictive dermopathy 369
 Resume 3
 Retiform hemangioendothelioma 377
 RF, *see* Radiofrequency (RF)
 Rheumatoid arthritis (RA) 109, 111, 125, 131–132
 Rosacea 29
 Roseola infantum 392
 Rotation grading and examinations 3
 Rotations 7
 – audition rotations 7
 – core rotations (third year) 7
 – elective rotations (third year/fourth year) 7
 Rothmund–Thomson syndrome (RTS) 389
 RTS, *see* Rothmund–Thomson syndrome (RTS)
 Rubella/congenital rubella syndrome 392

S

Sarcoidosis 100
 – and dermatological impact 124
 Saucerization 277
 Scalpel handle 259
 SCAP, *see* Syringocystadenoma papilliferum (SCAP)
 Scar improvement 298, 298
 Scarring 303
 Scarring alopecia 166
 – *See also* Cicatricial alopecia
 SCC, *see* Squamous cell carcinoma (SCC)
 SCID, *see* Severe combined immunodeficiency (SCID)
 Scissors 259, 277
 Sclerema neonatorum 362
 Scleroderma 143
 – *See also* Systemic sclerosis
 – after cosmetic surgery 117
 – localized cutaneous manifestations 143
 – prevalence and mechanism 143
 – systemic cutaneous manifestations 143
 – diffuse cutaneous systemic sclerosis 143
 – limited cutaneous systemic sclerosis (CREST syndrome) 146
 Sclerosing disorders in dermatology 115
 – cellular mechanisms of fibrosis 116
 – connective tissue diseases and 116
 – cancer risk in 116
 – nailfold capillaroscopy (NFC) 117
 – scleroderma after cosmetic surgery 117
 – epidemiology and clinical relevance 115
 – pathophysiological insights 115
 – rare scleroderma-like disorders 116
 Sclerotherapy 344
 – postsclerotherapy complications 345
 – sclerosing solutions 344, 345
 Sclerotherapy and treatment of leg veins 342
 – pathophysiology 342
 – telangiectasias and reticular veins, techniques for treating 342
 – compression 344
 – laser and radiofrequency ablation 346
 – sclerotherapy 344
 Sebaceous 227
 Sebaceous neoplasms 86–87
 Seborrheic dermatitis 35
 – diagnostic approach for 35
 – key clinical findings in 35
 – pertinent facts or medical associations for 36
 – treatment options for 36
 Seborrheic keratosis 210
 Secondary syphilis 165
 Segmental infantile hemangioma 362
 Senile/actinic purpura 82
 Sensory innervation
 – of ears 234
 – of feet 234
 – of hands 234
 – of head and neck, hands, and feet 233
 Severe combined immunodeficiency (SCID) 387
 Severity-Weighted Assessment Tool (SWAT) score 200
 Sexual abuse 147
 Shadowing 6
 Shave 277
 Shulman's disease 96–97
 Silicone 329
 Silk 255
 Silver hair syndromes 364
 Simple interrupted epidermal stitch 279
 Simple running epidermal stitch 279
 Sjögren's syndrome 109, 111
 SIIA, *see* Systemic juvenile idiopathic arthritis (SIIA)
 Sjogren's syndrome 173
 Sjogren's syndrome 109
 SJS, *see* Stevens–Johnson syndrome (SJS)
 Skin 21
 – and hair follicle 22
 – functions of 21
 – melanocytes and pigmentation 21
 – structure 21, 23
 – wound healing 22
 Skin cancers 29
 Skin grafts 297
 Skin hooks 261
 Skin lines 233
 Skin-limited cutaneous polyarteritis nodosa 84
 SLE, *see* Systemic lupus erythematosus (SLE)
 Small vessel 83
 – urticarial vasculitis 83
 Small/medium vessel (mixed) 83

– antineutrophil cytoplasmic antibody-associated vasculitis 83
 – cryoglobulinemic vasculitis, types II/III 83, 84
 – Henoch–Schönlein purpura/IgA vasculitis 83
 Sodium bicarbonate 250
 Soft tissue fillers 325
 – complications 330, 331
 – FDA approved fillers 326
 – filler types 325
 – autologous fat 329
 – calcium hydroxylapatite 327
 – tips and injection techniques 329, 330
 Solar lentigines 90
 Solo practice 421
 Sonidegib 271
 Specimen handling 280
 Spiradenoma 88
 Spironolactone 193
 Spitting sutures 302
 Spondyloarthropathies 125
 Spongiotic 225
 Sports-related conditions 147
 Squamous cell carcinoma (SCC) 29, 267
 – clinical presentation 267
 – genetic alterations 268
 – pathogenesis 267
 SS, *see* Sweet's Syndrome (SS)
 SSS, *see* Stiff skin syndrome (SSS)
 Standardized medical licensing examinations (USMLE/NBOME) 3
 – USMLE Step 1 and/or COMLEX Level 1, preparing for 3
 – USMLE Step 2/COMLEX Level 2 4
 Staph scalded skin syndrome 363
 Stasis dermatitis 43
 – diagnostic approach for 43
 – key clinical findings for 43
 – pathogenesis for 43
 – pertinent facts/medical associations 43
 – treatment for 43
 Stevens–Johnson syndrome (SJS) 49, 70, 75
 – and toxic epidermal necrolysis 171
 Stiff skin syndrome (SSS) 370

- Stitches 295
 Sturge–Weber syndrome (SWS) 383
 – diagnosis 383
 – epidemiology and genetics 383
 – pathophysiology 383
 – symptoms 383
 – treatment 383
 Subacute cutaneous lupus erythematosus 106
 Subcorneal disorders 46
 – pemphigus foliaceus 46
 Subepidermal disorders 48
 – bullous pemphigoid 48
 – dermatitis herpetiformis 48
 – epidermolysis bullosa acquisita 48
 – linear immunoglobulin A 49
 – porphyria cutanea tarda 48
 – Stevens–Johnson syndrome/toxic epidermal necrolysis 49
 Sublingual leukoplakia 174
 Substance use 147
 – physical and sexual abuse 147
 – sports-related conditions 147
 Subungual melanoma 169
 Success, setup for 3
 – curriculum vitae (CV)/resume 3
 – mentorship 3
 Successful applicant, characteristics of 9, 9
 Superficial facial fascia 240
 Superficial musculoaponeurotic system 238
 Superficial radiation therapy 272
 Surface markers 18
 Surgical complications 299
 – intraoperative complications 301
 -- bleeding 301
 -- nerve damage 301
 – postoperative complications 301
 -- dehiscence 302
 -- hematoma 302, 303
 -- necrosis 302
 -- scarring 303
 -- spitting sutures 302
 -- surgical site infection 301
 – preoperative considerations 299
 -- antibiotic prophylaxis 299
 -- bleeding, potential for 299
 -- implantable cardioverter-defibrillators and pacemakers 301
 -- surgical site identification 300
 -- identification 300
 Surgical instruments 259
 – blades 259
 – curettes and comedone extractors 262
 – drains 262
 – electro-surgery devices 262
 – for eyes, ears, nails, and oral cavity 263
 – forceps 261
 – hemostats 261
 – needle driver 261
 – scalpel handle 259
 – scissors 259
 – skin hooks 261
 Surgical site identification 300
 Surgical site infection 301
 Suture 253
 – absorbable 254
 – nonabsorbable 255
 – properties 254
 – suture size and needle size 253
 SWAT score, *see* Severity-Weighted Assessment Tool (SWAT) score
 Sweat gland tumors 87, 87
 Sweet’s Syndrome (SS) 94–95
 SWS, *see* Sturge–Weber syndrome (SWS)
 Syringocystadenoma papilliferum (SCAP) 87–88
 Syringoma 87
 Systemic diseases in dermatological conditions 123
 – amyloidosis and skin 126
 – arthropathies and dermatologic manifestations 124
 – atopic dermatitis as a systemic condition 123
 – calcifying and ossifying disorders 127
 – cutaneous manifestations of renal disease 124
 – depositional diseases and skin 126
 – inflammatory bowel disease and cutaneous manifestations 125
 – mucinoses and skin 126
 – sarcoidosis and dermatological impact 124
 – systemic lupus erythematosus (SLE) 123
 – systemic vasculitides and dermatotics 125
 Systemic juvenile idiopathic arthritis (SJIA) 125
 Systemic lupus erythematosus (SLE) 109, 111, 123, 140
 – cutaneous manifestations 143
 – dermatological aspects of 105
 -- acute cutaneous lupus erythematosus 105
 -- chronic cutaneous lupus erythematosus (CCLE) 107
 -- subacute cutaneous lupus erythematosus 106
 – epidemiology of 105
 – prevalence and mechanism 140
 Systemic sclerosis 132
 Systemic vasculitides and dermatologic manifestations 125
- T**
 TADA, *see* Triage amalgamated dermatoscopic algorithm (TADA)
 Takayasu arteritis 84
 Targeted systemic therapy 271
 – hedgehog signaling pathway inhibitors (vismodegib, sonidegib) 271
 – programmed-death receptor-1 inhibitors (cemiplimab, pembrolizumab) 271
 Tattoo removal endpoints 339
 TE, *see* Telogen effluvium (TE)
 Telangiectasias 342
 Telangiectasias and reticular veins, techniques for treating 342
 – compression 344
 – laser and radiofrequency ablation 346
 -- cyanoacrylate embolization 346
 – sclerotherapy 344
 -- postsclerotherapy complications 345
 -- sclerosing solutions 344, 345
 Telemedicine 422
 Telogen effluvium (TE) 164
 Temple area 244
 Temple/lateral brow area 241
 TEN, *see* Toxic epidermal necrolysis (TEN)
 Thrombotic thrombocytopenic purpura (TTP) 82
 Tinea capitis 165
 Tirbanibulin 191
 Topical anesthetics 251
 Topical chemotherapeutic agents 270
 – 5-fluorouracil 270
 – imiquimod 270
 Topical retinoids 190
 Topical steroids 189
 Topical therapy, principles of 189
 Topical vitamin D analogs 190
 Total nail avulsion 291
 Toxic epidermal necrolysis (TEN) 49, 70
 Traditional research year 5
 TRAPS, *see* Tumor necrosis factor receptor-associated periodic syndrome (TRAPS)
 Traumatic mucosal lesions 171
 Triage amalgamated dermatoscopic algorithm (TADA) 214
 – first step 214
 – second step 214
 – third step 214
 Triazoles 138
 Trichilemmoma 86
 Trichodiscoma 87
 Trichoepitheliomas 86
 Trichothiodystrophy (TTD) 389
 Trichotillomania 165
 Trigeminal nerve 233
 Trigeminal nerve distribution 237
 TSC, *see* Tuberous sclerosis complex (TSC)
 TTD, *see* Trichothiodystrophy (TTD)
 TTP, *see* Thrombotic thrombocytopenic purpura (TTP)
 Tuberous sclerosis 173
 Tuberous sclerosis complex (TSC) 90, 140, 381
 – cutaneous manifestations 140
 – diagnosis 381
 – epidemiology and genetics 381
 – pathophysiology 381
 – prevalence and genetics 140
 – symptoms 381
 – treatment 381
 Tumescence anesthesia 250
 Tumescence liposuction 347
 Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) 372
 Tumor suppressor genes 265
 Tumors 226
- U**
 U.S. Medical Licensing Examination (USMLE)
 – USMLE Step 1 and/or COMLEX Level 1, preparing for 3

- USMLE Step 2/COMLEX Level 2 **4**
 - Ulnar nerve **234**
 - Ultraviolet (UV) radiation **17**
 - UVA **17, 202**
 - UVB **17, 202**
 - UVC **17**
 - Ultraviolet (UV) therapy **197**
 - advancements in **202**
 - antimicrobial photodynamic therapy and clinical guidelines **204**
 - innovations and targeted approaches **203**
 - ongoing research **202**
 - potential future applications and technological innovations **204**
 - background and evolution of **197**
 - basic principles of **197**
 - clinical applications of **198**
 - dermatological conditions, broader spectrum of **201**
 - for cutaneous T-cell lymphoma/mycosis fungoides **200**
 - in atopic dermatitis **201**
 - in managing psoriasis **198**
 - in vitiligo repigmentation **199**
 - common and rare side effects **201**
 - delivery methods in **198**
 - patient monitoring and management, guidelines for **202**
 - pediatric dermatology, special considerations in **201**
 - safety profile **201**
 - types of **198**
 - Undermining planes **238**
 - United States Medical Licensing Examination (USMLE) **9, 9**
 - Urticaria **55, 55, 61**
 - Urticaria factitia **62**
 - Urticarial vasculitis **83**
 - USMLE, *see* U.S. Medical Licensing Examination (USMLE), United States Medical Licensing Examination (USMLE)
 - UV radiation, *see* Ultraviolet (UV) radiation
 - UV therapy, *see* Ultraviolet (UV) therapy
- V**
- Variable vessel **84**
 - Behcet's disease **84**
 - Varicella **394**
 - Varicella-zoster virus (VZV) **30**
 - Varicose veins **342**
 - Vascular danger zones **243**
 - glabella area **243**
 - infraorbital area **245**
 - nasal area **245**
 - nasolabial area **246**
 - perioral area **246**
 - temple area **244**
 - Vascular endothelial growth factor (VEGF) **266**
 - Vascular endpoints **338**
 - lentiginous endpoints **339**
 - Vascular lasers **272**
 - Vascular lesions, treatment of **335**
 - Vascular malformations **379**
 - arteriovenous malformations (AVMs) **380**
 - cutaneous capillary malformations (port wine stains) **379**
 - lymphatic malformations **379**
 - venous malformations **379**
 - Vascular tumors **228–229**
 - Vascular tumors and malformations **376**
 - benign tumors **376**
 - angiomatosis **376**
 - epithelioid hemangioma **376**
 - hemangioma **376**
 - lymphangioma **376**
 - intermediate (locally aggressive) **377**
 - kaposiform hemangioendothelioma **377**
 - intermediate (rarely metastasizing) **377**
 - composite hemangioendothelioma **378**
 - Kaposi's sarcoma (KS) **378**
 - papillary intralymphatic angioendothelioma **377**
 - retiform hemangioendothelioma **377**
 - malignant tumors **378**
 - cutaneous angiosarcoma **379**
 - epithelioid hemangioendothelioma **378**
 - vascular malformations **379**
 - arteriovenous malformations (AVMs) **380**
 - cutaneous capillary malformations (portwine stains) **379**
 - lymphatic malformations **379**
 - venous malformations **379**
 - VEGF, *see* Vascular endothelial growth factor (VEGF)
 - Venous malformations **379**
 - Venous system of head and neck **238**
 - Verruca vulgaris **168**
 - Vertical mattress stitch **279**
 - Vesiculobullous disorders **46**
 - intraepidermal disorders **46**
 - paraneoplastic pemphigus **48**
 - pemphigus vegetans **48**
 - pemphigus vulgaris **46**
 - subcorneal disorders **46**
 - pemphigus foliaceus **46**
 - subepidermal disorders **48**
 - bullous pemphigoid **48**
 - dermatitis herpetiformis **48**
 - epidermolysis bullosa acquisita **48**
 - linear immunoglobulin A **49**
 - porphyria cutanea tarda **48**
 - Stevens–Johnson syndrome/toxic epidermal necrolysis **49**
 - Viral exanthems and infectious diseases of childhood **392**
 - macular **392**
 - maculopapular **392**
 - papular **393**
 - vesicular **393**
 - Viral infections **136, 136**
 - diagnostic approach **136**
 - key clinical findings **136**
 - pertinent facts/medical associations **137**
 - treatment options **136**
 - Visiting Student Learning Opportunities (VSLO) portal **10**
 - Vismodegib **271**
 - Vitamin D **190**
 - Vitiligo **88**
 - Vitiligo repigmentation, PUVA and NBUB in **199**
 - case studies and long-term outcomes **200**
 - patient selection criteria and treatment protocols **200**
 - Volunteering **6**
 - VSLO portal, *see* Visiting Student Learning Opportunities (VSLO) portal
 - VZV, *see* Varicella-zoster virus (VZV)
- W**
- Waardenburg's syndrome (WS) hyperpigmentation **365**
 - WDS forum **6**
 - Wells' syndrome **96**
 - Werner syndrome **389**
 - WHIM syndrome **388**
 - Wiskott–Aldrich syndrome **387**
 - Wound care **297**
 - Wound closure **278**
 - Wound dressing supplies **294**
 - Wound healing **22**
 - WS hyperpigmentation, *see* Waardenburg's syndrome (WS) hyperpigmentation
- X**
- X-linked agammaglobulinemia (XLA) **388**
 - Xeroderma pigmentosum (XP) **388**
 - Xerosis **124**
 - XLA, *see* X-linked agammaglobulinemia (XLA)
 - XP, *see* Xeroderma pigmentosum (XP)
- Z**
- Zygomatic eminence, region lateral to **242**